A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
- Status
- WITHDRAWN
- Phase
- PHASE2
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab in HIV-1 Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Biomarker-based Study in R/M SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
- Status
- COMPLETED
- Phase
- PHASE1
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
- Status
- TERMINATED
- Phase
- PHASE2